The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study
Open accessAbstract
We conducted a double-blind, placebo-controlled, study of 19 patients fulfilling eligibility criteria for multifocal motor neuropathy with persistent conduction block. They were enrolled and divided into two groups: those who had never been treated previously with intravenous immunoglobulins (IVIg) (Group 1: 10 patients) and those who presented recurrent symptoms after previously successful treatment with IVIg (Group 2: nine patients). They were randomized prospectively to receive either IVIg or placebo at a dose of 500 mg/kg/day for 5 consecutive days, once a month for 3 months. At month 4, patients found to be responders remained on the same treatment for the 3 following months, while non-responders were switched to the alternative study drug for the 3 following months. Clinical assessment was conducted with the MRC score in 28 muscles and a self-evaluation scale (five daily motor activities scored from 0 to 5). In Group 1, nine patients completed the study, of whom initially four received IVIg and five placebo; four patients responded to IVIg (two at months 4 and 7, and a further two at month 7 after switching treatment at month 4), two patients responded to placebo at months 4 and 7, and three patients did not respond to either treatment. In Group 2, nine patients completed the study. Five patients first received IVIg and all responded at months 4 and 7. Four patients first received placebo and none responded at month 4; all were then switched to IVIg and three responded at month 7. When the 18 patients were considered together, seven out of the nine patients who received IVIg first were responders at month 4, compared with two of the nine patients who received placebo first, a difference that was statistically significant (P = 0.03). On the other hand, there was no significant difference in MRC score but a significant difference in the self-evaluation score, at month 4, between IVIg patients and placebo patients. Electrophysiological studies did not show significant differences at month 4 in motor parameters between IVIg patients and placebo patients. IgM anti-GM1 titres did not change significantly in patients treated with IVIg compared with those who received placebo, between baseline, month 4 and month 7. However, of five patients who had significantly high anti-GM1 titres (>3200) at baseline, four responded to IVIg. This trial confirms that IVIg is a promising therapeutic option for multifocal motor neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside
Pestronk, A., Cornblath, D. R., Ilyas, A. A., Baba, H., Quarles, R. H., Griffin, J. W., Alderson, K., & Adams, R. N. (1988) · Annals of Neurology · doi:10.1002/ana.410240113 · Cited by 609
Multifocal demyelinating neuropathy with persistent conduction block
Lewis, R. A., Sumner, A. J., Brown, M. J., & Asbury, A. K. (1982) · Neurology · doi:10.1212/wnl.32.9.958 · Cited by 502
Hahn, A. F., Bolton, C. F., Pillay, N., Chalk, C., Benstead, T. J., Bril, V., Shumak, K. H., Vandervoort, M. K., & Feasby, T. E. (1996) · Brain · doi:10.1093/brain/119.4.1055 · Cited by 409
Multifocal acquired demyelinating neuropathy masqurading as motor neuron disease
Parry, G. J., & Clarke, S. (1988) · Muscle & Nerve · doi:10.1002/mus.880110203 · Cited by 286
Van den Berg, L. H., Kerkhoff, H., Oey, P. L., Franssen, H., Mollee, I., Vermeulen, M., Jennekens, F. G., & Wokke, J. H. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.3.248 · Cited by 254
Multifocal motor neuropathy: Response to human immune globulin
Chaudhry, V., Corse, A. M., Cornblath, D. R., Kuncl, R. W., Drachman, D. B., Freimer, M. L., Miller, R. G., & Griffin, J. W. (1993) · Annals of Neurology · doi:10.1002/ana.410330303 · Cited by 218
Motor Neuropathy with Proximal Multifocal Persistent Conduction Block, Fasciculations and Myokymia
Roth, G., Rohr, J., Magistris, M. R., & Ochsner, F. (1986) · European Neurology · doi:10.1159/000116045 · Cited by 160
Inter‐laboratory validation of an ELISA for the determination of serum anti‐ganglioside antibodies
Willison, H. J., Veitch, J., Swan, A. V., et al. (1999) · European Journal of Neurology · doi:10.1046/j.1468-1331.1999.610071.x · Cited by 136
Maisonobe, T., Chassande, B., Vérin, M., Jouni, M., Léger, J., & Bouché, P. (1996) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.61.1.36 · Cited by 126
Self-citationThe long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy
van den Berg, L. H. (1998) · Brain · doi:10.1093/brain/121.3.421 · Cited by 106
Cited by
Peripheral neuropathies and anti-glycolipid antibodies
Willison, H. J. (2002) · Brain · doi:10.1093/brain/awf272 · Cited by 710
Update on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
ORANGE, J., HOSSNY, E., WEILER, C., BALLOW, M., BERGER, M., BONILLA, F., BUCKLEY, R., CHINEN, J., ELGAMAL, Y., & MAZER, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.015 · Cited by 653
Joint Task Force of the EFNS and the PNS (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00290.x · Cited by 568
Willison, H. J. (2001) · Brain · doi:10.1093/brain/124.10.1968 · Cited by 297
Metadata
- Authors
- Leger, J.-M., Chassande, B., Musset, L., Meininger, V., Bouche, P., & Baumann, N.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-01-01
- Volume
- 124
- Issue
- 1
- Pages
- 145-153
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2173374326
- Cited by
- 279
- References
- 15
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1093/brain/124.1.145
- The paper
- Leger, J.-M., Chassande, B., Musset, L., Meininger, V., Bouche, P., & Baumann, N. (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study. Brain. https://doi.org/10.1093/brain/124.1.145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.